Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Status:
Completed
Trial end date:
2014-10-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess efficacy and safety of belinostat in participants with
relapsed or refractory peripheral T-cell lymphoma (PTCL), who failed at least one prior
systemic therapy.